Detailed performance report for BRISTOL MYERS SQUIBB CO covering Q3 2026. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.
Summary of Financial Performance: Bristol Myers Squibb delivered a strong Q3 2026, with total revenue up 7% year over year to $13.1 billion. Growth portfolio sales rose 12% to $7.7 billion, driven by broad-based strength across key products including Eliquis ($4.7 billion, +26%), Reblozyl (+22%), Breyanzi (+48%), Camzyos (+42%), and Cobenfy (+33%). Opdivo declined 6% due to conversion to Qvantig, while Qvantig continued strong momentum with $334 million in revenue and an annualized run rate above $1.3 billion. Gross margin was 68.4%, operating expenses were $4.1 billion, and diluted EPS was $1.35. The company also generated about $4.2 billion in operating cash flow and ended the quarter with roughly $13 billion in cash and marketable securities.
Company Outlook & Strategy: Management raised full-year 2026 guidance, including non-GAAP EPS to $6.35–$6.55, reflecting strong year-to-date execution. The company emphasized continued momentum in its growth portfolio, successful pipeline derisking, and a disciplined cost structure. Key strategic priorities include translating pipeline progress into filings and launches, improving R&D speed and efficiency, and maintaining financial flexibility for business development, reinvestment, and shareholder returns. Leadership highlighted confidence in long-term growth, supported by eight growth portfolio products annualizing above $1 billion based on Q3 sales.
Key Industry Trends: The call pointed to strong demand in oncology, cardiometabolic, immunology, and neuroscience, alongside continued innovation in targeted protein degradation, radiopharmaceuticals, and CAR-T. Broader industry themes included the need for differentiated therapies in hard-to-treat diseases such as multiple myeloma, pulmonary fibrosis, and lupus. Management also noted increasing importance of community oncology participation, outpatient adoption, and global regulatory momentum for novel therapies.
Operational Highlights: Bristol Myers Squibb announced major manufacturing investments, including a ~$2.3 billion Houston campus expected to create nearly 500 jobs and a $170 million radiopharmaceutical facility in Indiana with up to 100 new jobs. Commercially, Symvexis launched positively with encouraging early physician feedback, strong interest in community and hospital settings, and a focus on simplicity and efficacy. The company also noted expansion of Camzyos into pediatric obstructive HCM, continued launch progress for Qvantig, and strong commercial execution across the portfolio.
Challenges & Risks: Legacy portfolio revenue is expected to decline 3%–5% for the full year, pressured by generic erosion and Eliquis LOE in Europe. Opdivo continues to face conversion pressure from Qvantig. In development, admilparant’s higher-dose data were less definitive, with the 120 mg dose showing improvement in FVC but not statistical significance. Management also acknowledged the inherent difficulty of clinical development in diseases like IPF and ongoing uncertainty around future readouts.
Key Analyst Questions & Responses: Analysts asked about admilparant’s mixed high-dose results; management said the 60 mg dose met the primary endpoint with favorable safety, while the 120 mg dose is still being analyzed and will be discussed with regulators. Another question focused on early Symvexis launch traction; management reported positive early uptake, favorable physician feedback, adoption across community and academic settings, and confidence in meaningful commercial potential, especially as more data are presented at ASH.
Access the official earnings call transcript for BRISTOL-MYERS-SQUIBB-CO 2026 Q3. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.